Skip to content
DataLookout
Menu

NCT04890613

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 19 versions: 16 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 48 words
    • Enrollment closed, study ongoing
    • Study sites: 8 to 7
    • Secondary endpoints: details revised at 1 of 3 entries
  2. Notable Primary and study completion dates pushed to Mar 2027v17
  3. Notable Primary completion date: Dec 2024 to Dec 2025v16 Show 4 more changesShow less
    • Eligibility criteria expanded, about 36 words
    • Study completion date: Jun 2025 to Dec 2026
    • Secondary endpoints: details revised at 3 of 3 entries
    • Site details revised at 1 of 8 sites
  4. Notable Primary completion date: Dec 2023 to Dec 2024
    • Study completion date: Jun 2024 to Jun 2025
    v15
  5. Minor Study sites: 7 to 8v13
Show 10 earlier versionsHide 10 earlier versions
  1. Minor Site details revised at 1 of 7 sitesv12
  2. Minor Study sites: 6 to 7v11
  3. Minor Site details revised at 2 of 6 sitesv10
  4. Minor Study sites: 4 to 6v9
  5. Minor Site details revised at 1 of 4 sitesv8
  6. Minor Study sites: 3 to 4v7
  7. Notable Primary completion date: Jun 1, 2023 to Dec 2023
    • Study sites: 2 to 3
    • Study completion date: Sep 30, 2025 to Jun 2024
    v6
  8. Minor Study sites: 1 to 2
    • Start date changed from estimate of Jul 2021 to Sep 8, 2021
    v4
  9. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 1, 2021 to Jul 2021
    • Site details revised
    v3
  10. Minor Start date: May 10, 2021 to Jun 1, 2021
    • Study description shortened, about 285 words
    • Study title expanded, about 4 words
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Determination of Recommended Phase 2 Dose (RP2D)
Timeframe: Safety cohort review will be conducted every 4 weeks from the date of first patient's enrollment to review safety data, until all patients have been enrolled and evaluated for toxicity.

Secondary (3)

Adverse Event (AE)
Objective Response
Patient-Reported Outcomes (PRO)

Arms and interventions

Main Study Cohort patients receiving CX-5461 at 250mg/m2Experimental

Eligible patients with histologically confirmed pancreatic, ovarian, prostate, or breast cancers with pathogenic/likely pathogenic germline or somatic BRCA1/2 and/or PALB2 mutation and/or genetic alterations in the specified genes will be enrolled to receive CX-5461 at a dosing concentration of 250mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.

Exploratory cohort patients receiving CX-5461 at 250mg/m2Experimental

Eligible patients with ovarian cancer and pathogenic/likely pathogenic BRCA1 and/or other HRD-associated mutation will be enrolled to receive CX-5461 at a dosing concentration of 250 mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.

Main Study Cohort patients receiving CX-5461 at 325mg/m2Experimental

After confirming the dose of 250mg/m2 to be safe and tolerable, eligible patients with histologically confirmed pancreatic, ovarian, prostate, or breast cancers with pathogenic/likely pathogenic germline or somatic BRCA1/2 and/or PALB2 mutation and/or genetic alterations in the specified genes will be enrolled to receive CX-5461 at a dosing concentration of 325mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.

Exploratory cohort patients receiving CX-5461 at 325mg/m2Experimental

After confirming the dose of 250mg/m2 to be safe and tolerable, eligible patients with ovarian cancer and pathogenic/likely pathogenic BRCA1 and/or other HRD-associated mutation will be enrolled to receive CX-5461 at a dosing concentration of 325 mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.

Drugs: CX-5461

Sites

7 sites in 2 countries

United States 5, Canada 2